|
1
|
Mueller SO, Clark JA, Myers PH and Korach
KS: Mammary gland development in adult mice requires epithelial and
stromal estrogen receptor alpha. Endocrinology. 143:2357–2365.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrangeli E, Lubrano C, Ortolani F,
Ravenna L, Vacca A, Sciacchitano S, Frati L and Gulino A: Estrogen
receptors: New perspectives in breast cancer management. J Steroid
Biochem Mol Biol. 49:327–331. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rose C, Thorpe SM, Andersen KW, Pedersen
BV, Mouridsen HT, Blichert-Toft M and Rasmussen BB: Beneficial
effect of adjuvant tamoxifen therapy in primary breast cancer
patients with high oestrogen receptor values. Lancet. 1:16–19.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choi HK, Yang JW, Roh SH, Han CY and Kang
KW: Induction of multidrug resistance associated protein 2 in
tamoxifen-resistant breast cancer cells. Endocr Relat Cancer.
14:293–303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clarke R, Thompson EW, Leonessa F, Lippman
J, McGarvey M, Frandsen TL and Brünner N: Hormone resistance,
invasiveness and metastatic potential in breast cancer. Breast
Cancer Res Treat. 24:227–239. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim MR, Choi HK, Cho KB, Kim HS and Kang
KW: Involvement of Pin1 induction in epithelial-mesenchymal
transition of tamoxifen-resistant breast cancer cells. Cancer Sci.
100:1834–1841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bui QT, Im JH, Jeong SB, Kim YM, Lim SC,
Kim B and Kang KW: Essential role of Notch4/STAT3 signaling in
epithelial-mesenchymal transition of tamoxifen-resistant human
breast cancer. Cancer Lett. 390:115–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim MR, Choi HS, Yang JW, Park BC, Kim JA
and Kang KW: Enhancement of vascular endothelial growth
factor-mediated angiogenesis in tamoxifen-resistant breast cancer
cells: Role of Pin1 overexpression. Mol Cancer Ther. 8:2163–2171.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer Cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berishaj M, Gao SP, Ahmed S, Leslie K,
Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is
tyrosine-phosphorylated through the interleukin-6/glycoprotein
130/Janus kinase pathway in breast cancer. Breast Cancer Res.
9:R322007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vignais ML, Sadowski HB, Watling D, Rogers
NC and Gilman M: Platelet-derived growth factor induces
phosphorylation of multiple JAK family kinases and STAT proteins.
Mol Cell Biol. 16:1759–1769. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vainchenker W and Constantinescu SN:
JAK/STAT signaling in hematological malignancies. Oncogene.
32:2601–2613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Furqan M, Mukhi N, Lee B and Liu D:
Dysregulation of JAK-STAT pathway in hematological malignancies and
JAK inhibitors for clinical application. Biomark Res. 1:52013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu K, Gao H, Wang Q, Wang L, Zhang B, Han
Z, Chen X, Han M and Gao M: Hispidulin suppresses cell growth and
metastasis by targeting PIM1 through JAK2/STAT3 signaling in
colorectal cancer. Cancer Sci. 109:1369–1381. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X,
Li J, Li C, Yan M, Zhu Z, et al: IL-6 secreted by cancer-associated
fibroblasts promotes epithelial-mesenchymal transition and
metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Oncotarget. 8:20741–20750. 2017.PubMed/NCBI
|
|
19
|
Wei Z, Jiang X, Qiao H, Zhai B, Zhang L,
Zhang Q, Wu Y, Jiang H and Sun X: STAT3 interacts with Skp2/p27/p21
pathway to regulate the motility and invasion of gastric cancer
cells. Cell Signal. 25:931–938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Quintás-Cardama A, Vaddi K, Liu P,
Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, et
al: Preclinical characterization of the selective JAK1/2 inhibitor
INCB018424: Therapeutic implications for the treatment of
myeloproliferative neoplasms. Blood. 115:3109–3117. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim ST, Jeon YW, Gwak H, Kim SY and Suh
YJ: Synergistic anticancer effects of ruxolitinib and calcitriol in
estrogen receptor-positive, human epidermal growth factor receptor
2-positive breast cancer cells. Mol Med Rep. 17:5581–5588.
2018.PubMed/NCBI
|
|
22
|
Tavallai M, Booth L, Roberts JL, McGuire
WP, Poklepovic A and Dent P: Ruxolitinib synergizes with DMF to
kill via BIM+BAD-induced mitochondrial dysfunction and via reduced
SOD2/TRX expression and ROS. Oncotarget. 7:17290–17300. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tavallai M, Booth L, Roberts JL,
Poklepovic A and Dent P: Rationally repurposing ruxolitinib (Jakafi
(®)) as a solid tumor therapeutic. Front Oncol.
6:1422016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Auerbach R, Kubai L, Knighton D and
Folkman J: A simple procedure for the long-term cultivation of
chicken embryos. Dev Biol. 41:391–394. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JS, Kang Y, Kim JT, Thapa D, Lee ES
and Kim JA: The anti-angiogenic and anti-tumor activity of
synthetic phenylpropenone derivatives is mediated through the
inhibition of receptor tyrosine kinases. Eur J Pharmacol.
677:22–30. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Religa P, Cao R, Religa D, Xue Y,
Bogdanovic N, Westaway D, Marti HH, Winblad B and Cao Y: VEGF
significantly restores impaired memory behavior in Alzheimer's mice
by improvement of vascular survival. Sci Rep. 3:20532013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Al Zaid Siddiquee K and Turkson J: STAT3
as a target for inducing apoptosis in solid and hematological
tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
31
|
Marson LP, Kurian KM, Miller WR and Dixon
JM: The effect of tamoxifen on breast tumour vascularity. Breast
Cancer Res Treat. 66:9–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kongkaneramit L, Sarisuta N, Azad N, Lu Y,
Iyer AK, Wang L and Rojanasakul Y: Dependence of reactive oxygen
species and FLICE inhibitory protein on lipofectamine-induced
apoptosis in human lung epithelial cells. J Pharmacol Exp Ther.
325:969–977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garcia-Becerra R, Santos N, Diaz L and
Camacho J: Mechanisms of resistance to endocrine therapy in breast
cancer: Focus on signaling pathways, miRNAs and genetically based
resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Goetz MP, Rae JM, Suman VJ, Safgren SL,
Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart
DA, et al: Pharmacogenetics of tamoxifen biotransformation is
associated with clinical outcomes of efficacy and hot flashes. J
Clin Oncol. 23:9312–9318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hosford SR and Miller TW: Clinical
potential of novel therapeutic targets in breast cancer: CDK4/6,
Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
Pharmgenomics Pers Med. 7:203–215. 2014.PubMed/NCBI
|
|
37
|
Smith IE, Walsh G, Skene A, Llombart A,
Mayordomo JI, Detre S, Salter J, Clark E, Magill P and Dowsett M: A
phase II placebo-controlled trial of neoadjuvant anastrozole alone
or with gefitinib in early breast cancer. J Clin Oncol.
25:3816–3822. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Johnston SR, Martin LA, Leary A, Head J
and Dowsett M: Clinical strategies for rationale combinations of
aromatase inhibitors with novel therapies for breast cancer. J
Steroid Biochem Mol Biol. 106:180–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Matthes T, Manfroi B and Huard B:
Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol
Hematol. 105:1–4. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taga T, Hibi M, Hirata Y, Yamasaki K,
Yasukawa K, Matsuda T, Hirano T and Kishimoto T: Interleukin-6
triggers the association of its receptor with a possible signal
transducer, gp130. Cell. 58:573–581. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Shea JJ, Schwartz DM, Villarino AV,
Gadina M, McInnes IB and Laurence A: The JAK-STAT pathway: impact
on human disease and therapeutic intervention. Annu Rev Med.
66:311–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aparicio-Siegmund S, Sommer J, Monhasery
N, Schwanbeck R, Keil E, Finkenstädt D, Pfeffer K, Rose-John S,
Scheller J and Garbers C: Inhibition of protein kinase II (CK2)
prevents induced signal transducer and activator of transcription
(STAT) 1/3 and constitutive STAT3 activation. Oncotarget.
5:2131–2148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Buchert M, Burns CJ and Ernst M: Targeting
JAK kinase in solid tumors: Emerging opportunities and challenges.
Oncogene. 35:939–951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang S, Luo C, Gu Q, Xu Q, Wang G, Sun H,
Qian Z, Tan Y, Qin Y, Shen Y, et al: Activating JAK1 mutation may
predict the sensitivity of JAK-STAT inhibition in hepatocellular
carcinoma. Oncotarget. 7:5461–5469. 2016.PubMed/NCBI
|
|
47
|
Lee S, Shah T, Yin C, Hochberg J, Ayello
J, Morris E, van de Ven C and Cairo MS: Ruxolitinib significantly
enhances in vitro apoptosis in Hodgkin lymphoma and primary
mediastinal B-cell lymphoma and survival in a lymphoma xenograft
murine model. Oncotarget. 9:9776–9788. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
49
|
Bharti AC, Donato N and Aggarwal BB:
Curcumin (diferuloylmethane) inhibits constitutive and
IL-6-inducible STAT3 phosphorylation in human multiple myeloma
cells. J Immunol. 171:3863–3871. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Stover DG, Gil Del Alcazar CR, Brock J,
Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R,
et al: Phase II study of ruxolitinib, a selective JAK1/2 inhibitor,
in patients with metastatic triple-negative breast cancer. NPJ
Breast Cancer. 4:102018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee HJ, Seo NJ, Jeong SJ, Park Y, Jung DB,
Koh W, Lee HJ, Lee EO, Ahn KS, Ahn KS, et al: Oral administration
of penta-O-galloyl-β-D-glucose suppresses triple-negative breast
cancer xenograft growth and metastasis in strong association with
JAK1-STAT3 inhibition. Carcinogenesis. 32:804–811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Garg M: Epithelial plasticity and cancer
stem cells: Major mechanisms of cancer pathogenesis and therapy
resistance. World J Stem Cells. 9:118–126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Smigiel JM, Parameswaran N and Jackson MW:
Potent EMT and CSC phenotypes are induced by Oncostatin-M in
pancreatic cancer. Mol Cancer Res. 15:478–488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Huang Y, de Reyniès A, de Leval L, Ghazi
B, Martin-Garcia N, Travert M, Bosq J, Brière J, Petit B, Thomas E,
et al: Gene expression profiling identifies emerging oncogenic
pathways operating in extranodal NK/T-cell lymphoma, nasal type.
Blood. 115:1226–1237. 2010. View Article : Google Scholar : PubMed/NCBI
|
